They summarized a large variety of STAT3 inhibitors which reverse cisplatin resistance in lung cancer, ovarian cancer, cervical cancer, breast cancer, laryngeal cancer, head and neck cancers, esophageal cancer, and hepatocellular carcinoma [52]. The gene discussed is STAT3; the disease is ovarian cancer.